Alnylam Pharmaceuticals
ALNY
#634
Rank
C$44.47 B
Marketcap
$344.85
Share price
-0.80%
Change (1 day)
52.05%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2023 (TTM): -$5.50

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is -$5.74. In 2022 the company made an earnings per share (EPS) of -$12.98 a decrease over its 2021 EPS that were of -$10.06.

EPS history for Alnylam Pharmaceuticals from 2003 to 2023

Annual EPS

Year EPS Change
2023 (TTM)-$5.50-57.65%
2022-$12.9829.03%
2021-$10.06-3.36%
2020-$10.41-8.48%
2019-$11.377.67%
2018-$10.5639.74%
2017-$7.5612.94%
2016-$6.6938.84%
2015-$4.82-32.88%
2014-$7.18259.44%
2013-$2.00-31.25%
2012-$2.9152.94%
2011-$1.9030.77%
2010-$1.45-8.77%
2009-$1.5978.13%
2008-$0.89-70.78%
2007-$3.0699.09%
2006-$1.54-43.88%
2005-$2.74-82.33%
2004-$15.50-59.23%
2003-$38.02

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
-$2.38-58.64%๐Ÿ‡บ๐Ÿ‡ธ USA
$52.20-1,009.00%๐Ÿ‡บ๐Ÿ‡ธ USA
-$10.94 90.51%๐Ÿ‡บ๐Ÿ‡ธ USA
-$0.38-93.43%๐Ÿ‡บ๐Ÿ‡ธ USA
-$2.36-58.88%๐Ÿ‡บ๐Ÿ‡ธ USA
$5.23-191.00%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
$4.44-177.38%๐Ÿ‡ซ๐Ÿ‡ท France
-$2.79-51.34%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel